Newest first. 5.2k questions across 107 tags.
Numbers first: cagrilintide · 4 mg/mL. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
Numbers first: a GLP-1 receptor agonist · 40 °C · seven days. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is…
Details up front: cagrilintide · ATTAIN-1. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
What I have: 8 mg · 4 mg/mL. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary; the method is what I am…
The nausea followed exactly the pattern I was told to expect: bad for a fortnight after each dose step, better by week four, essentially gone by month five. The…
Concretely: 40 mg · 0.5 mL · 0.9% sodium chloride · a GLP-1 receptor agonist. The failure mode I am trying to avoid is making this decision emotionally. I have twelve…
This is a first order from this supplier, so I have no track record to reason from. The failure mode I am trying to avoid is making this decision emotionally. I have…
Conditions: SELECT · tirzepatide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is there…
For reference: QYB · HJ · the United States. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…
The specifics, since they change the answer: REDEFINE-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to…
For reference: 50 mg · survodutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to reason…
I have the plan documents and the written criteria, which took two calls to obtain. I would like the mechanism, because I want to be able to reason about the cases…
The particulars: fibrillation · semaglutide · 30 °C. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have…
For reference: 97.6% · PeptideMeter · 95.2%. An unexpected observation, and I would like a differential rather than reassurance. The conditions were within what I…
For reference: fibrillation · survodutide · 2–8 °C. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have…
Every supplier sheet I have says "store lyophilised powder at −20 °C for long-term, 2–8 °C for short-term, room temperature acceptable for shipping". Nobody explains…
What I am working with: orforglipron · PIONEER-1. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My…
Stated plainly: orforglipron · 5 mg/mL · sixteen weeks. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…
What I am working with: 98.2% · sampling plan. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I am working with: 5 mg · 3 mL. I have worked this out and I would like someone to find the error, because I suspect there is one. My working so far, for the…
Stated plainly: ALT · AST · semaglutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints are…
Numbers first: FLOW · retatrutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
I have kept every message, invoice and document, which I gather is the useful habit. I can do the algebra. I am not confident about the conversion factors. If there…
Details up front: SELECT · early satiety · 4 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…